173435-78-4

Basic information

• Product Name: BOC-9-AMINONONANOIC ACID
• Synonyms: BOC-9-AMINONONANOIC ACID;BOC-9-ANC-OH;N-TERT-BUTYLOXYCARBONYL-9-AMINO-NONANOIC ACID;N-T-BUTYLOXYCARBONYL-9-AMINO-NONANOIC ACID;Boc-9-aminononane acid;9-((tert-Butoxycarbonyl)aMino)nonanoic acid;Nonanoic acid, 9-[[(1,1-dimethylethoxy)carbonyl]amino]-;Boc-9-aminononanoic acid≥ 98% (HPLC)
• CAS NO: 173435-78-4
• Molecular Formula: C14H27NO4
• Molecular Weight: 273.37
• Product Categories: Amino Acids
• Mol File: 173435-78-4.mol

Chemical Properties

• Boiling Point: 418.8±28.0 °C(Predicted)
• Appearance: /
• Density: 1.025±0.06 g/cm3(Predicted)
• Storage Temp.: Store at 0°C
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: BOC-9-AMINONONANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-9-AMINONONANOIC ACID(173435-78-4)
• EPA Substance Registry System: BOC-9-AMINONONANOIC ACID(173435-78-4)

Safety Data

• Hazardous Substances Data: 173435-78-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-9-AMINONONANOIC ACID is used as a PROTAC linker for the synthesis of proteolysis-targeting chimeras (PROTACs) to facilitate the development of novel therapeutic strategies. The compound's ability to form stable amide bonds with primary amine groups and its Boc-protected amino groups make it a valuable component in the creation of these protein degradation tools, which have the potential to target and degrade specific proteins involved in various diseases.
Used in Chemical Synthesis:
BOC-9-AMINONONANOIC ACID is used as a building block in chemical synthesis, particularly for the development of new compounds with potential applications in various industries, such as pharmaceuticals, materials science, and agrochemicals. The compound's unique structure and reactivity allow for the creation of diverse molecules with specific properties and functions.
Used in Research and Development:
BOC-9-AMINONONANOIC ACID is utilized as a research tool in the study of protein degradation mechanisms and the development of new protein-targeting strategies. Its role as a PROTAC linker enables researchers to explore the potential of protein degradation as a therapeutic approach for various diseases, including cancer and neurodegenerative disorders.

Upstream product

• 1120-12-3 9-aminononanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites

N-Myristoyltransferase (NMT) has been shown to be essential in Leishmania and subsequently validated as a drug target in Plasmodium. Herein, we discuss the use of antifungal NMT inhibitors as a basis for inhibitor development resulting in the first sub-micromolar peptidomimetic inhibitors of Plasmodium and Leishmania NMTs. High-resolution structures of these inhibitors with Plasmodium and Leishmania NMTs permit a comparative analysis of binding modes, and provide the first crystal structure evidence for a ternary NMT-Coenzyme A/myristoylated peptide product complex. This journal is

COVALENT INHIBITION OF BACTERIAL QUORUM SENSING

Inhibitors of bacterial communication, such as quorum sensing, and method of use and manufacture thereof.

Covalent inhibition of bacterial quorum sensing

Chemical coordination of gene expression among bacteria as a function of population density is regulated by a mechanism known as 'quorum sensing' (QS). QS in Pseudomonas aeruginosa, an opportunistic pathogen that causes disease in immunocompromised patients, is mediated by binding of the transcriptional activator, LasR, to its ligand, 3-oxo-C12-HSL, leading to population-wide secretion of virulence factors and biofilm formation. We have targeted QS in P. aeruginosa with a set of electrophilic probes designed to covalently bind Cys79 in the LasR binding pocket, leading to specific inhibition of QS-regulated gene expression and concomitant reduction of virulence factor secretion and biofilm formation. This first example of covalent modification of a QS receptor provides a new tool to study molecular mechanisms of bacterial group behavior and could lead to new strategies for targeting bacterial virulence.

Cyclic imino derivatives and pharmaceutical compositions containing them

The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.